HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Entrada Therapeutics (NASDAQ:TRDA) and maintained a $25 price target.
August 09, 2023 | 10:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Entrada Therapeutics (NASDAQ:TRDA) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $25.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Entrada Therapeutics. The maintained price target of $25 indicates the firm's continued confidence in the company's potential. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100